|
FY2026
12 months to Feb 28, 2026
|
FY2025
12 months to Feb 28, 2025
|
FY2024
12 months to Feb 29, 2024
|
FY2023
12 months to Feb 28, 2023
|
FY2022
12 months to Feb 28, 2022
|
|
|---|---|---|---|---|---|
| Net income | |||||
| Operating activities | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Depreciation | |||||
| Amortization of intangibles | |||||
| Amortization of right of use asset | |||||
| Stock based compensation | |||||
| Net realized and unrealized (gains) losses on investments | |||||
| Accrued interest income on short-term investments | |||||
| Accrued interest expense on contingent consideration | |||||
| Accrued interest expense on finance lease | |||||
| Gain on purchase | |||||
| Deferred income tax benefit | |||||
| Changes in Operating Assets and Liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Other assets, non-current | |||||
| Accounts payable | |||||
| Contingency consideration | |||||
| Customer deposits | |||||
| Accrued expenses, other current and non-current liabilities | |||||
| Net cash provided by operating activities | |||||
| Investing activities | |||||
| Proceeds from sale of marketable securities | |||||
| Purchases of marketable securities | |||||
| Purchases of short-term investments | |||||
| Maturities of short-term investments | |||||
| Cash paid for acquisition, net of cash acquired | |||||
| Purchases of long-term investments | |||||
| Payment of contingent consideration | |||||
| Purchases of property and equipment | |||||
| Net cash (used in) investing activities | |||||
| Financing activities | |||||
| Stock repurchase | |||||
| Proceeds from sale of stock | |||||
| Proceeds on mortgage loan | |||||
| Payments on finance lease liabilities | |||||
| Principal payments on mortgage loan | |||||
| Net cash provided by financing activities | |||||
| Financing right of use asset assumed through lease liability | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents - beginning of the year | |||||
| Cash and cash equivalents - end of period | |||||
| Financing right of use asset assumed through lease liability | |||||
| Supplemental disclosures of cash flow data | |||||
| Income taxes paid | |||||
| Interest expense paid | |||||
Loading...